RRRonit Reich‐Slotky

Ronit Reich‐Slotky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ronit Reich‐Slotky has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • How do I save cell therapy product's storage space?

    by Grace H. Kim, Nita Patel, Ronit Reich‐Slotky

    BackgroundAvailability of liquid nitrogen (LN2) freezer storage space is a major challenge for many transplant programs as they continue to grow and accumulate products. The recent trend of allogeneic grafts cryopreservation that started during the COVID-19 pandemic, made the situation even worse requiring an increase in storage capacity. Multi-compartment cryopreservation bags can help save storage space but can be tricky to use. Here, we describe the validation of muti-compartment cryopreservation bags for the purpose of donor lymphocyte infusion (DLI) aliquots. MethodsWe validated the use of five compartment cryobags for cryopreservation of cell therapy products. Four products were cryopreserved using these bags and each compartment was tested post-thaw for product volume distribution, total cell count recovery, and viability. Additionally, the integrity of both bag compartments and labels was assessed as well. ResultsAll tested specimens met post-thaw viability and TNC recovery acceptability criteria. Fill volume was optimized at 24-25 mL for acceptable volume distribution between aliquots. With proper heat sealing between compartments, all aliquots retain their integrity and cryopreservation labels were adherent and legible. ConclusionsMuti-compartment bags can be used successfully for cryopreservation of cell therapy products and increase storage capacity.

  • Cryopreserved hematopoietic stem/progenitor cells stability program‐development, current status and recommendations: A brief report from the AABB‐ISCT joint working group cellular therapy product stability project team

    by Ronit Reich‐Slotky, Ljiljana V. Vasovic, Kevin J. Land, Mike Halpenny, Joan Woeltz, Aby J. Mathew, Diane Fournier, Brenda Alder, Karl Stasko, Nadim Mahmud

    The AABB-ISCT Joint Working Group Stability Project Team (SPT) was assigned to roadmap a path toward standardization of cryopreserved hematopoietic stem/progenitor cell (HSPC) stability programs. HSPC stability encompasses a broad scope of conditions including non-frozen ("fresh") and cryopreserved cell products, and varying methods for storage, thaw, and administration. This report assessed current practices and focused solely on cryopreserved HSPC cell therapy products to establish preliminary recommendations for a stability program roadmap. A survey was prepared by the SPT and distributed to ISCT and AABB members. Survey results were summarized and recommendations were outlined based on the responses from the survey. This report highlights current practices for cryopreserved HSPC stability programs, including additional considerations and recommendations. Eighty-two (82) centers worldwide participated in the survey. Survey results indicate variability across programs. HSPC stability depends on multiple factors within the processing facility (e.g., cryopreservation techniques, reagents used, and storage temperature) and independent variables (e.g., donor-related factors and starting material variability). While retention of hematopoietic engraftment potential is the primary goal for cryopreserved HSPC stability, engraftment results should not be used as the sole metric for stability programs. Based on the survey results, the SPT provides recommendations for consideration. The SPT recommendations for best practices are not intended to replace existing standards. The survey results emphasize the need for the community to optimize best practices and consider initiating collaborative projects to improve the standardization of cryopreserved HSPC stability programs for cell therapy products.


  • Open Access

    Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation

    by Sarah S. Makhani, Samir P. Oza, Ronit Reich-Slotky, Pashna N. Munshi, Noa Biran, Michele L. Donato, David S. Siegel, David H. Vesole, Suzan Naam, Scott D. Rowley


  • Validation of automated fluorescent‐based technology for measuring total nucleated cell viability of hematopoietic progenitor cell products

    by Kanan A. Patel, Nita Patel, Grace H. Kim, Laura S. Chape, Kristianne Gail D. Agbon, Minnie P. Angulo Fuentes, Francis‐Marie L. Barbosa, Ryan T. Castellano, Gloria N. Gonzalez, Sheeba Mathew, et al.

    Background: A reliable rapid method for measuring total nucleated cell (TNC) viability is essential for cell‐based products manufacturing. The trypan blue (TB) exclusion method, commonly used to measure TNC viability of hematopoietic progenitor cell (HPC) products, is a subjective assay, typically uses a microscope, and includes a limited number of cells. The NucleoCounter NC‐200 is an automated fluorescent‐based cell counter that uses pre‐calibrated cartridges with acridine orange and DAPI dyes to measure cell count and viability. This study describes the validation of the NC‐200 for testing HPC's viability.Methods: Samples from 189 fresh and 60 cryopreserved HPC products were included. Fresh products were tested for viability after collection by both TB and NC‐200. 7‐aminoactinomycin D (7AAD) CD45+ cell viability results were obtained from a flow cytometry test. Cryopreserved products thawed specimens were tested for viability by both TB and NC‐200. The NC‐200 viability results were compared with the other methods. Acceptability criteria were defined as ≤10% difference between the NC‐200 method and the other methods for at least 95% of the samples.Results: Fresh products' mean viability difference between NC‐200 and TB or 7AAD CD45+ method was 4.9% (95%CI 4.6–5.4) and 2.8% (95%CI 2.2–3.4), respectively. Thawed products' mean viability difference between NC‐200 and TB was 3.0% (95%CI 0.4–5.6).Conclusion: The NC‐200 automated fluorescent‐based method can be used effectively to determine HPC's viability for both fresh and cryopreserved products. It can help eliminate human bias and provide consistent data and operational ease.


  • How do I: Evaluate the safety and legitimacy of unproven cellular therapies?

    by Indira Guleria, Maria de Los Angeles Muñiz, Matthew Wilgo, Asawari Bapat, Wanxing Cui, Yen‐Michael Sheng Hsu, Madhan Jeyaraman, Sathish Muthu, Federico Rodriguez, Andrew Fesnak, et al.

    Background: Unproven cellular therapies are being offered to patients for a variety of conditions and diseases for which other treatments have failed. The use of untested cellular therapies is a worldwide problem. Practitioners (e.g., physicians, scientists, QA/QI facility managers, and policy advocates) are perhaps unaware of the risks involved with such therapies. Therefore, a critical need exists to bring attention to the potential limitations and adverse effects of these therapies to inform and limit misinformation.Study Design and Methods: We describe the extent of the unproven cellular therapy problem through a search of scientific literature and social media coverage. We also describe the regulatory framework that can be used by the practitioner to review and evaluate both proven and unproven cellular therapies.Results: We report on the current state of unproven cellular therapies across the globe. A workflow to facilitate an understanding of the regulatory processes involved in the approval of cellular therapies is provided as well as a list of warnings required by regulatory agencies on various products. It is hoped that this article will serve as a tool kit to educate the practitioner on navigating the field of unproven cellular therapy products.Discussion: Increasing awareness of the issues associated with unproven therapies through education is important to help in reducing misinformation and risks to patients.


  • How do I transfer liquid nitrogen freezers to a new home safely?

    by Ronit Reich‐Slotky

    Background: Our cell processing facility was planning to transfer more than 20 Liquid Nitrogen (LN2) freezers to a new location. Moving LN2 freezers is a complex task that can pose potential risk to the storage units' integrity as well as to the products that they hold. Careful planning is required, especially when moving multiple freezer units at once.Methods: To achieve the task, we put together a detailed project plan, collaborated with all the involved partners, hired qualified professionals to perform the project‐specific tasks, and put together a detailed risk assessment and risk mitigation plan.Results: A facility was chosen and prepared according the project plan and safety department recommendations. Risk mitigation strategies were developed and implemented, and all freezers were transfered uneventfully to a new location.Conclusions: By performing detailed planning and engaging the appropriate partners, LN2 freezers can be successfully transferred to a new home.


  • Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products

    by Ronit Reich-Slotky, Sarah S. Makhani, Ljiljana V. Vasovic, Roger N. Pearse, Adriana Rossi, Adrianne Philips, Melissa M. Cushing, Amrita D. Singh, Koen van Besien

    Washing cryopreserved peripheral blood stem cell (PBSC) products can decrease infusion-related adverse reactions but can also result in cell loss and reduced cell viability. To assess the risk and benefit of washing products, we compared the time to neutrophil and platelet engraftment between autologous patients that received washed products (n = 201) and non-washed products (n = 89). The effect of the other variables, including age, gender, diagnosis, transplant dose, method of stem cell mobilization, and growth factor support regimen post-transplant, was assessed. In multivariate analysis, direct thaw and infusion of non-washed products resulted in significantly faster neutrophil engraftment (p = .003) and platelet engraftment (p = .017) than washed products. The mean neutrophil and platelet engraftment times were 1.07 days faster and 2.27 days faster, respectively. In conclusion, direct thaw and infusion of cryopreserved PBSC without washing results in significantly shorter time to recovery of neutrophils and platelets after autologous transplantation.